Primary Aldosteronism in a Hispanic Cohort: Responses to Mineralocorticoid Receptor Antagonism and Remission in a Case

Vista sencilla de ítem
dc.contributor.authorTapia-Castillo, Alejandra
dc.contributor.authorVecchiola, Andrea
dc.contributor.authorQuiñones, Paola
dc.contributor.authorBaudrand, René
dc.contributor.authorUslar, Thomas
dc.contributor.authorDelgado, José
dc.contributor.authorCarvajal, Cristian A.
dc.contributor.authorFardella, Carlos E.
dc.coverage.spatialUnited Kingdom
dc.date.accessioned2026-02-23T17:47:20Z
dc.date.available2026-02-23T17:47:20Z
dc.date.issued2025-02
dc.description.abstractBackground: Primary aldosteronism (PA) is the main cause of secondary arterial hypertension. In this study, we present the medical treatment of Hispanic patients with PA followed for up to 5 years, highlighting the complete cure with pharmacological treatment in one of our patients. Methods: We studied 32 PA patients, followed every 6 months after starting MRA. A clinical response was the normalization of blood pressure (BP) in the absence of other antihypertensive drugs. The biochemical response was considered with normalization of potassium and renin. Responses to treatment were compared using the defined daily dose (DDD). The effect of MRA was evaluated in vitro. The HAC15 cells were cultured and stimulated with aldosterone and spironolactone for 24-72 h, and the apoptotic cell death was measured. Results: At 12 months posttreatment with MRA, 68% of the patients had a total clinical response, and 67% had a total biochemical response. Response to MRA treatment reduced DDD by an average of 74%. Additionally, we observed one PA patient treated with spironolactone after 3 years, he presented a pharmacological cure with normalization of aldosterone and renin without treatment with spironolactone. The in vitro study shows that spironolactone increased early apoptosis by 60% and late apoptosis by 50%. Conclusions: These results suggest the importance of timely diagnosis of PA and specific treatment with MRA, especially in patients with a poor response to treatment. Moreover, remission of PA may occur in some patients after spironolactone treatment due to its suggestive role as an apoptotic agent.
dc.identifier.citationAmerican Journal of Hypertension, Vol. 38, N° 6 (2025) p. 354-360
dc.identifier.doihttps://doi.org/10.1093/ajh/hpaf020
dc.identifier.issne1941-7225
dc.identifier.orcidhttps://orcid.org/0000-0002-6081-1468
dc.identifier.urihttps://hdl.handle.net/20.500.12254/7456
dc.language.isoen
dc.publisherOxford University Press
dc.rightsAtribución-NoComercial-CompartirIgual 3.0 Chile (CC BY-NC-SA 3.0 CL)
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/cl/
dc.subjectBlood pressure
dc.subjectHypertension
dc.subjectMineralocorticoid receptor
dc.subjectPrimary aldosteronism
dc.titlePrimary Aldosteronism in a Hispanic Cohort: Responses to Mineralocorticoid Receptor Antagonism and Remission in a Case
dc.typeArticle
Archivos
Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
2025_Primary Aldosteronism in a Hispanic Cohort- Responses to MR.pdf
Tamaño:
682.32 KB
Formato:
Adobe Portable Document Format
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
347 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
Artículos de Revistas